Preliminary results from two early-phase clinical trials suggest that the investigational drug ibrutinib may benefit some patients with an aggressive type of non-Hodgkin lymphoma (NHL). The treatment was well tolerated, with only minor side effects.
Two patients in the phase I trial had a complete response, one had a partial response, and a fourth patient who had not responded to any prior treatment had substantial tumor regression and a major improvement in his symptoms. One patient with a complete response continues to take the oral therapy daily and has shown no signs of disease for 16 months, Dr. Staudt stated. And the patient whose disease stabilized had enough tumor shrinkage to qualify for an allogeneic bone marrow transplant and is now in complete remission.
Drs. Staudt and Wilson are continuing their work with ibrutinib. “We’re already discussing strategies for the next trials,” Dr. Wilson said.
Read the full article here.